Ever Long Tablet

Potential pharmacokinetic interactions between dapoxetine, a serotonin transporter inhibitor developed for the treatment of premature ejaculation (PE), and phosphodiesterase-5 tadalafil and sildenafil inhibitors, agents used in the treatment of erectile dysfunction (ED), were investigated in an open label, randomized crossover study (n = 24 men ) comparing ever long tablet 60 mg, dapoxetine 60 mg + tadalafil 20 mg and dapoxetine 60 mg + sildenafil 100 mg. Plasma concentrations of dapoxetine, tadalafil and sildenafil were determined by liquid chromatography-tandem mass spectrometry. Tadalafil did not affect the pharmacokinetics of dapoxetine, while sildenafil increased dapoxetine AUCinf by 22%; these effects were not considered clinically significant. Dapoxetine did not appear to affect the pharmacokinetics of tadalafil or sildenafil. Most side effects were mild. Therefore, dapoxetine has no clinically significant pharmacokinetic interactions with tadalafil or sildenafil, and the comb